Latest news and press releases about Moleculin Biotech, Inc. (MBRX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs.
Price
| Price | $0.74 |
| Market Cap | $4M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.37 |
| EV / EBITDA | 0.10 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -816.56% |
| Return on Invested Capital | -242.25% |
| Return on Assets | -143.82% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ADAP · AIMD · APLM · ATHA · BLRX · CTXR · ICU
Explore sector: Healthcare · Biotechnology
More sections of MBRX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks